Securities Lawsuit Filed Against Alto Neuroscience, Inc.

Alto Neuroscience, Inc. (NYSE: ANRO) faces a class action lawsuit alleging securities fraud, claiming that the company's public statements were materially false and misleading about its product pipeline, ALTO-100, and its clinical, regulatory, and commercial prospects. Investors who purchased or acquired Alto common stock or securities between February 2, 2024, and October 22, 2024, may be eligible for compensation.

Key Takeaways:

• The lawsuit seeks to recover losses on behalf of Alto Neuroscience, Inc. investors who were allegedly adversely affected by securities fraud.
• The class consists of all persons and entities that purchased or acquired Alto common stock or securities between February 2, 2024, and October 22, 2024.
• The complaint alleges that defendants made false statements and/or concealed that ALTO-100 was less effective in treating major depressive disorder than defendants had led investors to believe.
• The lawsuit claims that Alto's business and/or financial prospects were overstated due to the alleged misrepresentations.
• A lead plaintiff must be appointed by September 19, 2025, to share in any potential recovery.
• The process of filing a claim is free of out-of-pocket costs, and any potential recovery is not contingent upon serving as a lead plaintiff.

Statistics:

• February 2, 2024: Initial public offering (IPO) date for Alto Neuroscience, Inc.
• October 22, 2024: Date through which investors may have been affected by alleged securities fraud
• September 19, 2025: Deadline for requesting appointment as lead plaintiff
• 20 years: Levi & Korsinsky's experience representing investors in complex securities litigation
• 70 employees: Team size of Levi & Korsinsky to serve clients
• 7 years: Rank in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States